Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
Authors:
- Sylwester RogulaSRSylwester Rogula
- Ceren EyiletenCECeren Eyileten
- Marek PostułaMPMarek Postuła
- Łukasz SzarpakŁukasz Szarpak
- Krzysztof J. FilipiakKFKrzysztof J. Filipiak
- Marcin KurzynaMKMarcin Kurzyna
- Miłosz JaguszewskiMiłosz Jaguszewski
- Tomasz MazurekTMTomasz Mazurek
- Marcin GrabowskiMGMarcin Grabowski
- Aleksandra GąseckaAleksandra Gąsecka
Open Access
- 6 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 980718
Abstract
Pulmonary arterial hypertension (PAH) is characterized by remodeling of the pulmonary arteries, and defined by elevated pulmonary arterial pressure, measured during right heart catheterization. There are three main challenges to the diagnostic and therapeutic process of patients with PAH. First, it is difficult to differentiate particular PAH etiology. Second, invasive diagnostic is required to precisely determine the severity of PAH, and thus to qualify patients for an appropriate treatment. Third, the results of treatment of PAH are unpredictable and remain unsatisfactory. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post transcriptional gene-expression. Their role as a prognostic, and diagnostic biomarkers in many different diseases have been studied in recent years. MiRNAs are promising novel biomarkers in PAH due to their activity in various molecular pathways and processes underlying PAH. Lack of biomarkers to differentiate between particular PAH etiology and evaluate the severity of PAH, as well as paucity of therapeutic targets in PAH open a new field for the possibility to use miRNAs in these applications. In our article, we discuss the potential of miRNAs use as diagnostic tools, prognostic biomarkers and therapeutic targets in PAH.Keywords
This publication has 112 references indexed in Scilit:
- Therapeutic Cardiac‐Targeted Delivery of miR‐1 Reverses Pressure Overload–Induced Cardiac Hypertrophy and Attenuates Pathological RemodelingJournal of the American Heart Association, 2013
- MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary HypertensionCirculation, 2012
- Altered MicroRNA Processing in Heritable Pulmonary Arterial Hypertension: An Important Role for Smad-8American Journal of Respiratory and Critical Care Medicine, 2011
- Molecular Signature of a Right Heart Failure Program in Chronic Severe Pulmonary HypertensionAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Role for miR-204 in human pulmonary arterial hypertensionJournal of Experimental Medicine, 2011
- Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and MonocrotalineArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion FormationCirculation Research, 2009
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart diseaseHeart, 2006